U.S. Markets closed

Sigma-Aldrich launches CRISPRs

Zacks Equity Research

Sigma-Aldrich Corporation (:SIAL) announced that its biological products and services business – Sigma Life Science – has launched a novel editing tool Sigma CRISPRs. CRISPRs are a mammalian genome editing tool appropriate for screening and exploratory studies. They are inexpensive tools that can be used for the development of targeted gene editing.

Sigma-Aldrich CRISPRs are obtained from bacterial and archaeal immune defenses, which guard against invading viruses and foreign DNA. CRISPRs use customizable RNA–nuclease complexes that allow introduction of genome edits at a desired site in mammalian genomes with high efficiency.

Sigma-Aldrich also has an exclusive online bioinformatics tool where CRISPRs can be custom-designed. It is the only commercial tool that automatically applies CRISPR/Cas best design practices, including a minimum requirement of three base-pair mismatches between the target site and other sites in the genome, thereby reducing the possibility of off-target effects.

Researchers can request CRISPR/Cas targets obtained from their own design preferences or they can take the help of Sigma's expert CompoZr Zinc Finger Nuclease (:ZFN) bioinformatics team to produce a custom design based on cutting-edge public and proprietary CRISPR guidelines.

ZFNs are the gold standard in gene technology and have been instrumental in creating Sigma CRISPRs which provide researchers a quicker and more affordable way to screen genes of interest.

Sigma-Aldrich released its second quarter 2013 results in Jul. The company posted adjusted earnings of $1.05 per share, above the year-ago earnings of 97 cents. The results beat the Zacks Consensus Estimate of $1.03. The adjusted earnings exclude other charges of 7 cents a share.

Profit as reported, rose roughly 3.5% year over year to $119 million (or 98 cents per share) in the quarter from $115 million (or 94 cents per share) a year ago.

Net sales increased 3% year over year to $681 million in the reported quarter, surpassing the Zacks Consensus Estimate of $679 million. Organic sales growth in the quarter was 4%, while foreign exchange translation had a negative impact of 1%.

Adjusted operating margin for the second quarter was 26.1% compared with 25.8% recorded a year ago. Adjusted operating margin in the reported quarter excludes other charges of $12 million related to merger/acquisition activity and settlement of a licensing dispute.

Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).

Other companies in the specialty chemical space with favorable Zacks Rank are Ferro Corp. (:FOE), Minerals Technologies Inc. (:MTX) and Sensient Technologies Corp. (:SXT). While Ferro carries a Zacks rank#1 (Strong Buy), Minerals Technologies and Sensient Technologies retain a Zacks Rank #2 (Buy).

Read the Full Research Report on SIAL

Read the Full Research Report on SXT

Read the Full Research Report on FOE

Read the Full Research Report on MTX

Zacks Investment Research

More From Zacks.com